MHRA closes one IDAP authorisation as the pilot stays shut to new applicants
A small update to the UK's Innovative Devices Access Pathway page marks one authorisation closed. For quality teams, the lesson is about lifecycle tracking, not headlines.
What happened
On 19 November 2026 the MHRA revised its guidance page for the Innovative Devices Access Pathway (IDAP). The update shows that authorisation IDAP/DEU/009/2024/0001, described as an Unmet Clinical Need Authorisation, is now closed. The page also confirms that the IDAP pilot remains closed to new applicants.
The records say nothing beyond that. They do not name the device or the sponsor, and they give no reason for the closure. They do not say whether patients or users were transitioned to another route, or whether a successor scheme is planned. Anyone drawing conclusions about why the authorisation closed would be speculating.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- MHRA updates IDAP page as one Unmet Clinical Need Authorisation is closed MHRA · Thu 19 Nov 2026
- Health Canada flags Type I recall of Heraeus VascuPuncture PICC guidewires over coating particle risk Health Canada · Thu 19 Nov 2026
- Infarmed orders recall of Entecavir Viatris batches over active substance contamination concerns INFARMED · Thu 19 Nov 2026
- BfArM lists urgent field safety notice for Thermo Fisher's YEASTONE BROTH diagnostic product BfArM field safety notices · Thu 19 Nov 2026
- BfArM publishes Philips urgent field safety notice for Dual IBP Adapter BfArM field safety notices · Thu 19 Nov 2026
- Michigan home health agency owner jailed for four years over $1.6m Medicare kickback fraud US Department of Justice · Thu 19 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.